Checkpoint Therapeutics, Inc.
NASDAQ:CKPT
3.21 (USD) • At close January 8, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Checkpoint Therapeutics, Inc. |
Symbool | CKPT |
Munteenheid | USD |
Prijs | 3.21 |
Beurswaarde | 154,505,325 |
Dividendpercentage | 0% |
52-weken bereik | 1.38 - 4.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. James F. Oliviero III, C.F.A., CFA |
Website | https://www.checkpointtx.com |
An error occurred while fetching data.
Over Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)